• An allosteric inhibitor of AKT (protein kinase B)
    • Currently under investigation in phase 2 clinical trials for various solid tumors
    • Recommended phase 2 dose: 60 mg orally every other day on empty stomach, 2 hours before meal or 2 hours after meal
    • Half-life: A range of 63 to 89 hours
    • Metabolism: Major CYP3A4 substrate
    • Common side effects: Skin rash, stomatitis, nausea, pruritus, hyperglycemia, diarrhea
    (Yap et al., 2011)
    Other topics in Targeted and Immunotherapy Agents